家蚕溶茧酶基因的真核表达及其产物的生物活性检测

为了研究家蚕 Bombyx mori 溶茧酶基因 （cocoonae）真核表达及其产物的生物活性,将溶茧酶基因（GenBank 登录号 EF428980）克隆至杆状病毒转移载体 pFastBac^TM 1 中获得 pFast-cocoonase,将其转化 DH10Bac 感受态细胞后,PCR 方法检测证实所分离的重组病毒 DNA 中含有目的片段溶茧酶基因。用脂质体法 转染家蚕 BmN 细胞,获得重组病毒。SDS-PAGE 分析显示,感染重组杆状病毒 Bac-cocoonase 的细胞表达产物在约为 27.6 kD 处出现特异性条带,这与预测的蛋白大小相符。用该表达产物与茧丝反应后,电镜下观察茧丝的形态,结果表明表达产物对茧丝的丝胶层有一定的水解作用。     

Pulmonary type II cell hypertrophy and pulmonary lipoproteinosis are features of chronic IL-13 exposure

Interleukin (IL)-13, a key mediator of Th2-mediated immunity, contributes to the pathogenesis of asthma and other pulmonary diseases via its ability to generate fibrosis, mucus metaplasia, eosinophilic inflammation, and airway hyperresponsiveness. In these studies, we compared surfactant accumulation in wild-type mice and mice in which IL-13 was overexpressed in the lung. When compared with littermate controls, transgenic animals showed alveolar type II cell hypertrophy under light and electron microscopy. Over time, their alveoli also filled with surfactant in a pulmonary alveolar proteinosis pattern. At the same time, prominent interstitial fibrosis occurs. Bronchoalveolar lavage fluid from these mice had a three- to sixfold increase in surfactant phospholipids. Surfactant proteins (SP)-A, -B, and -C showed two- to threefold increases, whereas SP-D increased 70-fold. These results indicate that IL-13 is a potent stimulator of surfactant phospholipid and surfactant accumulation in the lung. IL-13 may therefore play a central role in the broad range of chronic pulmonary conditions in which fibrosis, type II cell hypertrophy, and surfactant accumulation occur.     

Countrywide Survey for MERS-Coronavirus Antibodies in Dromedaries and Humans in Pakistan

Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a zoonotic pathogen capable of causing severe respiratory disease in humans. Although dromedary camels are considered as a major reservoir host, the MERS-CoV infection dynamics in camels are not fully understood. Through surveillance in Pakistan, nasal (n = 776) and serum (n = 1050)samples were collected from camels between November 2015 and February 2018. Samples were collected from animal markets, free-roaming herds and abattoirs. An in-house ELISA was developed to detect IgG against MERS-CoV. A total of 794 camels were found seropositive for MERS-CoV. Prevalence increased with the age and the highest seroprevalence was recorded in camels aged [ 10 years (81.37%) followed by those aged 3.1–10 years (78.65%) and B 3 years (58.19%).Higher prevalence was observed in female (78.13%) as compared to male (70.70%). Of the camel nasal swabs, 22 were found to be positive by RT-qPCR though with high Ct values. Moreover, 2,409 human serum samples were also collected from four provinces of Pakistan during 2016–2017. Among the sampled population, 840 humans were camel herders.Although we found a high rate of MERS-CoV antibody positive dromedaries (75.62%) in Pakistan, no neutralizing antibodies were detected in humans with and without contact to camels.     

Estimates and Predictions of Coal Workers’ Pneumoconiosis Cases among Redeployed Coal Workers of the Fuxin Mining Industry Group in China: A Historical Cohort Study

This research was aimed at estimating possible Coal workers’ pneumoconiosis (CWP) cases as of 2012, and predicting future CWP cases among redeployed coal workers from the Fuxin Mining Industry Group. This study provided the scientific basis for regulations on CWP screening and diagnosis and labor insurance policies for redeployed coal workers of resource-exhausted mines. The study cohort included 19,116 coal workers. The cumulative incidence of CWP was calculated by the life-table method. Possible CWP cases by occupational category were estimated through the average annual incidence rate of CWP and males’ life expectancy. It was estimated that 141 redeployed coal workers might have suffered from CWP as of 2012, and 221 redeployed coal workers could suffer from CWP in the future. It is crucial to establish a set of feasible and affordable regulations on CWP screening and diagnosis as well as labor insurance policies for redeployed coal workers of resource-exhausted coal mines in China.     

人胱硫醚β合成酶原核表达纯化及鉴定

目的:构建人胱硫醚β合成酶(human cystathionineβ-synthase,hCBS)基因原核表达载体,在E.coli BL21(DE3)中表达,并进行纯化和酶活性检测。方法:以胰腺细胞cDNA文库为模板,采用聚合酶链式反应(PCR)扩增hCBS基因蛋白编码区的全序列,克隆入原核表达载体pET32a(+),构建重组质粒pET32a(+)-hCBS。经限制性内切酶双酶切及DNA序列分析鉴定目的基因后与人CBS基因(基因bank号:BT007154.1)完全一致,转入E.coli BL21(DE3)中,由IPTG诱导表达融合蛋白。结果:经SDS-PAGE、Western blot分析,证明诱导表达的蛋白为重组人CBS(rhCBS)。再由Ni-NTA树脂亲和层析,并脱盐冷冻干燥后获得重组rhCBS(约19 mg/L培养物),并测得其比活力约为57 kU/g。结论:成功地表达纯化出具有功能活性的重组蛋白rhCBS,为进一步研究该酶的相互作用蛋白以及其在生物学和临床科学的作用奠定了基础。     

天敌昆虫利用信息化学物质寻找寄主或猎物的研究进展

应用天敌昆虫控制害虫是传统生物防治中的主要内容。信息化学物质是天敌昆虫远距离向寄主或猎物栖息地进行定向,以及近距离对寄主或猎物进行定位所依赖的重要信号。综述了能够引诱天敌昆虫的信息化学物质的产生、分类、作用、异同及背景,并介绍了天敌昆虫对信息化学物质的行为反应和特异性。同时,对这类物质在生物防治中的应用及前景作了介绍与探讨。对不同营养层的种间化学通讯作为研究协同进化时的重要参考也作了简要介绍。     

Mapping one of the 2 genes controlling lemon ray flower color in sunflower (Helianthus annuus L.)

In an F2 population of 120 plants derived from a cross between 2 breeding lines with yellow ray flowers, we observed 111 plants with yellow-colored and 9 plants with lemon-colored ray flowers. The segregation pattern fits a 15:1 (chi2(15:1) = 0.32, P > 0.5) ratio, suggesting that the lemon ray flower color is conditioned by 2 independent recessive genes that had been contributed individually by each of the parents. We sampled 111 plants from the 3 F(2:3) families displaying a 3 to 1 segregating ratio for genotyping with molecular markers. One of the genes, Yf(1), was mapped onto linkage group 11 of the public sunflower map. A targeted region amplified polymorphism marker (B26P17Trap13-68) had a genetic distance of 1.5 cM to Yf(1), and one simple sequence repeat marker (ORS733) and one expressed sequence tag (EST)-based marker (HT167) previously mapped to linkage group 11 were linked to Yf(1) with distances of 9.9 and 2.3 cM, respectively.     

长效重组药物研究进展

生物重组药物半衰期的长短显著影响药物在使用时的剂量以及治疗的效果,所以延长其在体内的生物半衰期,防止药物在体内迅速降解成为现在药物研究的重要方向之一.针对目前较为广泛使用的几种重组药物长效化方法.如定点突变、化学修饰、基因融合、药物剂型和给药方式的改变等,结合目前已经上市的和正在研发中的长效重组药物进行了综述.